#### Tetrahedron 66 (2010) 8242-8246

Contents lists available at ScienceDirect

# Tetrahedron

journal homepage: www.elsevier.com/locate/tet

# Three-component reaction of N'-(2-alkynylbenzylidene)hydrazide, $\alpha$ , $\beta$ -unsaturated carbonyl compound, with bromine

# Hui Ren<sup>a</sup>, Shengqing Ye<sup>a</sup>, Fen Liu<sup>b</sup>, Jie Wu<sup>a,\*</sup>

<sup>a</sup> Department of Chemistry, Fudan University, 220 Handan Road, Shanghai 200433, China <sup>b</sup> Key Laboratory of Radioactive Geology and Exploration Technology Fundamental Science for National Defense, East China Institute of Technology, Fuzhou, Jiangxi 344000, China

#### ARTICLE INFO

Article history: Received 19 June 2010 Received in revised form 17 August 2010 Accepted 19 August 2010 Available online 26 August 2010

Keywords: N'-(2-Alkynylbenzylidene)hydrazide Bromine 6-Bromo-H-pyrazolo[5,1-a]isoquinoline 6-Bromo-1,2,3,10b-tetrahydropyrazolo-[5,1-a]isoquinoline α,β-unsaturated carbonyl compound

## ABSTRACT

Different outcomes were generated under different conditions for the three-component reaction of N'-(2-alkynylbenzylidene)hydrazide,  $\alpha$ , $\beta$ -unsaturated carbonyl compound, with bromine. 6-Bromo*H*-pyrazolo[5,1-*a*]isoquinoline was obtained when the reaction was performed in NMP at 70 °C in the presence of DABCO as base, while 6-bromo-1,2,3,10*b*-tetrahydropyrazolo[5,1-*a*]isoquinoline was afforded when the reaction occurred in DMAc at 10 °C in the presence of K<sub>3</sub>PO<sub>4</sub> as the base.

© 2010 Elsevier Ltd. All rights reserved.

## 1. Introduction

It is well recognized that the combination of methodology development and library approaches is an efficient device for the discovery of small-molecule enzyme inhibitors or receptor ligands.<sup>1</sup> Usually, the natural product-like compounds with privileged scaffolds are considered as an important source of small molecules. Among the skeletons, isoquinoline is a subunit in numerous naturally occurring alkaloids that exhibit a wide range of biological acitivities,<sup>2,3</sup> such as inhibitor of human topoisomerase I<sup>4</sup> and anti-HIV activity.<sup>5</sup> In continuation of our interest in the synthesis of bioactive heterocycles using tandem reactions,<sup>6</sup> we became interested to construct a focused library of isoquinolines. Recently, we have discovered several efficient strategies for the isoquinolines generation.<sup>7,8</sup> Among the compounds synthesized, *H*-pyrazolo[5,1*a*]isoquinolines are more attractive<sup>8</sup> since in our preliminary biological assays, these particular analogues show promising activity as PTP1B inhibitor. In order to search better hits, we need to rapidly prepare the diverse *H*-pyrazolo[5,1-*a*]isoquinolines. The synthetic route should have considerable flexibility to introduce a diversity of functionalities in a high-throughput manner.

As mentioned above, we reported an efficient approach for generation of *H*-pyrazolo[5,1-*a*]isoquinolines via silver triflatecatalyzed three-component reaction of 2-alkynylbenzaldehyde. sulfonohydrazide, and  $\alpha$ . $\beta$ -unsaturated carbonyl compound.<sup>8d</sup> In this reaction process, 2-alkynylbenzaldehyde condensed with sulfonohydrazide firstly to afford the N'-(2-alkynylbenzylidene)hydrazide, which then underwent endo-cyclization catalyzed by AgOTf to furnish the isoquinolinium-2-yl amide. After [3+2] cycloaddition of  $\alpha,\beta$ -unsaturated carbonyl compound and aromatization, *H*-pyrazolo[5,1-*a*]isoquinoline would be afforded. Inspired by this result, we envisioned that an electrophile might be involved in the reaction of N'-(2-alkynylbenzylidene)hydrazide with  $\alpha$ , $\beta$ -unsaturated carbonyl compound. As expected, the 6-bromo*H*pyrazolo[5,1-a]isoquinoline would be produced, which could be further elaborated using palladium-catalyzed cross-coupling reactions to introduce more diversity into the *H*-pyrazolo[5,1-*a*]isoquinoline scaffold. Herein, we would like to disclose our recent efforts for the three-component reaction<sup>9</sup> of N'-(2-alkynylbenzylidene)hydrazide,  $\alpha$ , $\beta$ -unsaturated carbonyl compound, with bromine. Interestingly, different outcomes were generated under different conditions. The desired 6-bromoH-pyrazolo[5,1-a]isoquinoline was obtained when the reaction was performed in NMP at 70 °C in the presence of DABCO, while 6-bromo-1.2.3.10b-tetrahydropyrazolo[5,1-*a*]isoguinoline was afforded when the reaction occurred in DMAc at 10 °C in the presence of K<sub>3</sub>PO<sub>4</sub>.





<sup>\*</sup> Corresponding author. Tel.: +86 21 6510 2412; fax: +86 21 6564 1740; e-mail address: jie\_wu@fudan.edu.cn (J. Wu).

<sup>0040-4020/\$ —</sup> see front matter @ 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.tet.2010.08.052

# 2. Results and discussion

As described previously, N'-(2-alkynylbenzylidene)hydrazide could be easily transferred to bromo-containing isoquinolinium-2yl amide in the presence of bromine.<sup>10</sup> In order to simplify the reaction optimization process, initial studies were carried out for the reaction of bromo-containing isoquinolinium-2-vl amide A1 with ethyl acrylate 2a (Scheme 1, Eq. 1). The reaction was complicated when MeCN was used as the solvent at 70 °C. To our delight, the result could be improved dramatically when the reaction occurred in DMAc, which afforded the desired product 3a in 63% yield. Higher yield was obtained when DMF was utilized as a replacement in the reaction (73% yield). Gratifyingly, compound 3a was isolated in 90% yield when the reaction took place in NMP. With this promising result in hand, we started to explore the three-component reaction of N'-(2-alkynylbenzylidene)hydrazide **1a**, ethyl acrylate 2a, with bromine (Scheme 1, Eq. 2). Since HBr would be generated during the reaction process, a base was added as a scavenger. After screening different bases (LiOH, K<sub>3</sub>PO<sub>4</sub>, DABCO, KOAc, Na<sub>2</sub>CO<sub>3</sub>, Et<sub>3</sub>N) for the above reaction in NMP at 70 °C, we realized that the reaction proceeded the most efficiently in the presence of 2.0 equiv of DABCO, leading to the desired product 3a in 65% yield.



**Scheme 1.** Initial studies for the three-component reaction of *N*′-(2-alkynylbenzylidene)hydrazide **1a**, ethyl acrylate **2a**, with bromine.

The optimized reaction condition mentioned above (DABCO 2.0 equiv in NMP at 70  $^{\circ}$ C) led us to examine the generality of the reaction for the synthesis of 6-bromoH-pyrazolo[5,1-a]isoquinolines (Table 1). As shown in Table 1, similar results were generated when methyl acrylate **2b** or *n*-butyl acrylate **2c** was employed as the substrate in the three-component reaction of N'-(2-alkynylbenzylidene)hydrazide 1a with bromine (Table 1, entries 2 and 3). When pent-1-en-3-one 2d was used as a partner in the above reaction, the corresponding product 3d was obtained in 55% yield (Table 1, entry 4). Reactions of chloro- or fluoro-substituted N'-(2alkynylbenzylidene)hydrazides 1 with ethyl acrylate 2a and bromine were examined meanwhile, which gave rise to the desired products in moderate yields (Table 1, entries 6-10). Substrates with alkyl (n-butyl and cyclopropyl) groups attached to the triple bond of N'-(2-alkynylbenzylidene)hydrazides **1** also worked well in the transformation (Table 1, entries 9–10). However, N'-(2-alkynylbenzylidene)hydrazide with electron-donating groups attached on the aromatic backbone effected the reaction remarkably, resulting in diminished reactivity. For instance, only a trace amount of product was detected when compound **1h** was employed in the reaction of ethyl acrylate 2a and bromine (Table 1, entry 11).

Similar to our previous report,<sup>8d</sup> for the reaction process we conceived that the bromine-mediated 6-*endo*-cyclization would occur firstly to generate the key intermediate isoquinolinium-2-yl amide **A**. After [3+2] cycloaddition reaction with  $\alpha$ , $\beta$ -unsaturated carbonyl compound **2**, compound **4** would be afforded. Subsequent

#### Table 1

Synthesis of 6-bromo*H*-pyrazolo[5,1-*a*]isoquinoline **3** via three-component reaction of *N*'-(2-alkynylbenzylidene)hydrazide **1**,  $\alpha$ , $\beta$ -unsaturated carbonyl compound **2**, with bromine





<sup>a</sup> Isolated yield based on N'-(2-alkynylbenzylidene)hydrazide **1**.

release of tosyl group and aromatization would produce 6-bromo*H*-pyrazolo[5,1-a]isoquinoline **3** (Scheme 2). To support the mechanistic proposal and illustrate the reaction process, reaction of bromo-containing isoquinolinium-2-yl amide **A1** with ethyl acrylate **2a** in different solvent was re-investigated. Indeed, under the standard conditions shown in Table 1, during the reaction process a new compound, which might be the key intermediate **4** could be

detected. However, the effort for separation of the compound was difficult since the compound was disappeared fast at 70 °C. We reasoned that the key intermediate might be isolated at lower temperature. To our delight, we observed the formation of compound **4a** with a 92% isolated yield when the reaction was performed in DMAc at 10 °C. In addition, we found that three-component reaction of *N'*-(2-alkynylbenzylidene)hydrazide **1**,  $\alpha$ , $\beta$ -unsaturated carbonyl compound **2**, with bromine in the presence of K<sub>3</sub>PO<sub>4</sub> as a base in DMAc at 10 °C proceeded efficiently to afford compound **4** in good yields (Scheme 3). However, compound **4** was not stable, which was easily decomposed after several minutes of storage.



**Scheme 2.** Possible mechanism for the three-component reaction of N'-(2-alky-nylbenzylidene)hydrazide,  $\alpha$ , $\beta$ -unsaturated carbonyl compound, with bromine.



**Scheme 3.** Generation of 6-bromo-1,2,3,10*b*-tetrahydropyrazolo[5,1-*a*]-isoquinoline **4** via three-component reaction of *N*-(2-alkynylbenzylidene)hydrazide **1**,  $\alpha$ , $\beta$ -unsaturated carbonyl compound **2**, with bromine.

# 3. Conclusions

In summary, we have described a three-component reaction of N'-(2-alkynylbenzylidene)hydrazide,  $\alpha$ , $\beta$ -unsaturated carbonyl compound, with bromine, which affords different results under different conditions. 6-Bromo*H*-pyrazolo[5,1-*a*]isoquinoline is generated when the reaction is performed in NMP at 70 °C in the presence of DABCO, while 6-bromo-1,2,3,10*b*-tetrahydropyrazolo [5,1-*a*]isoquinoline is obtained when the reaction occur in DMAc at 10 °C in the presence of K<sub>3</sub>PO<sub>4</sub>. This temperature-controlled result also gives us hits for the understanding of reaction process.

#### 4. Experimental section

# 4.1. General procedure for synthesis of 6-bromo*H*-pyrazolo-[5,1-*a*]isoquinoline 3 via three-component reaction of *N*-(2alkynylbenzylidene)hydrazide 1, $\alpha$ , $\beta$ -unsaturated carbonyl compound 2, with bromine

A mixture of N'-(2-alkynylbenzylidene)hydrazide **1** (0.2 mmol) and bromine (0.24 mmol, 1.2 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) was stirred at

room temperature under air atmosphere for 10 min. Then the temperature was elevated to 70 °C, and DABCO (0.3 mmol, 1.5 equiv) and  $\alpha$ , $\beta$ -unsaturated carbonyl compound (0.4 mmol, 2.0 equiv) were added into the reaction mixture. After completion of the reaction as indicated by TLC, the reaction was quenched with saturated NH<sub>4</sub>Cl (aq), extracted with ethyl acetate (10 mL×3). The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to provide the desired product **3**.

4.1.1. Ethyl 6-bromo-5-phenylpyrazolo[5,1-a]isoquinoline-1-carboxylate (**3a**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.97–9.94 (m, 1H), 8.38 (s, 1H), 8.33–8.30 (m, 1H), 7.77–7.73 (m, 2H), 7.62–7.57 (m, 3H), 7.51–7.49 (m, 2H), 4.43 (q, J=7.3 Hz, 2H), 1.43 (t, J=7.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  163.7, 145.4, 138.4, 137.6, 134.1, 130.2, 130.0, 129.7, 129.6, 129.4, 128.7, 127.9, 127.4, 123.8, 112.0, 108.1, 60.6, 14.4. HRMS (ESI) calcd for C<sub>20</sub>H<sub>15</sub>BrN<sub>2</sub>O<sub>2</sub>: 417.0215 (M+Na<sup>+</sup>), found: 417.0204.

4.1.2. Methyl 6-bromo-5-phenylpyrazolo[5,1-a]isoquinoline-1-carboxylate (**3b**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.95–9.93 (m, 1H), 8.37 (s, 1H), 8.32–8.28 (m, 1H), 7.78–7.73 (m, 2H), 7.62–7.57 (m, 3H), 7.51–7.49 (m, 2H), 3.95 (s, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  164.1, 145.4, 138.5, 137.6, 134.0, 130.3, 130.0, 129.7, 129.6, 128.7, 128.4, 127.9, 127.4, 123.7, 112.1, 107.7, 51.8. HRMS (ESI) calcd for C<sub>19</sub>H<sub>13</sub>BrN<sub>2</sub>O<sub>2</sub>: 403.0058 (M+Na<sup>+</sup>), found: 403.0050.

4.1.3. Butyl 6-bromo-5-phenylpyrazolo[5,1-a]isoquinoline-1-carboxylate (**3c**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.97–9.94 (m, 1H), 8.37 (s, 1H), 8.31–8.28 (m, 1H), 7.76–7.75 (m, 2H), 7.62–7.57 (m, 3H), 7.51–7.49 (m, 2H), 4.37 (t, *J*=6.6 Hz, 2H), 1.83–1.76 (m, 2H), 1.54–1.44 (m, 2H), 0.99 (t, *J*=7.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  163.9, 145.5, 138.6, 137.8, 134.2, 130.4, 130.2, 129.8, 129.7, 128.8, 128.7, 128.1, 127.5, 124.0, 112.1, 108.3, 64.7, 30.9, 19.5, 13.9. HRMS (ESI) calcd for C<sub>22</sub>H<sub>19</sub>BrN<sub>2</sub>O<sub>2</sub>: 445.0528 (M+Na<sup>+</sup>), found: 445.0510.

4.1.4. 1-(6-Bromo-5-phenylpyrazolo[5,1-a]isoquinolin-1-yl)propan-1-one (**3d**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  10.08–10.06 (m, 1H), 8.39 (s, 1H), 8.32–8.30 (m, 1H), 7.78–7.73 (m, 2H), 7.62–7.59 (m, 3H), 7.51–7.48 (m, 2H), 3.06 (q, *J*=7.3 Hz, 2H), 1.30 (t, *J*=7.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  195.3, 145.0, 137.8, 137.4, 134.1, 130.6, 130.0, 129.8, 129.7, 128.7, 128.6, 128.1, 127.3, 124.1, 116.6, 112.8, 34.7, 8.7. HRMS (ESI) calcd for C<sub>20</sub>H<sub>15</sub>BrN<sub>2</sub>O: 401.0265 (M+Na<sup>+</sup>), found: 401.0247.

4.1.5. *Ethyl* 6-bromo-5-*p*-tolylpyrazolo[5,1-*a*]isoquinoline-1-carboxylate (**3e**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.97–9.94 (m, 1H), 8.38 (s, 1H), 8.32–8.29 (m, 1H), 7.77–7.74 (m, 2H), 7.42–7.38 (m, 4H), 4.43 (q, *J*=6.9 Hz, 2H), 2.49 (s, 3H), 1.44 (t, *J*=6.9 Hz, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  163.8, 145.4, 139.7, 138.5, 137.8, 131.2, 130.2, 129.9, 129.7, 129.5, 128.6, 127.9, 127.4, 123.8, 112.0, 108.1, 60.6, 21.6, 14.4. HRMS (ESI) calcd for C<sub>21</sub>H<sub>17</sub>BrN<sub>2</sub>O<sub>2</sub>: 431.0371 (M+Na<sup>+</sup>), found: 431.0352.

4.1.6. *Ethyl* 6-bromo-9-chloro-5-phenylpyrazolo[5,1-a]isoquinoline-1-carboxylate (**3f**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  10.05–10.04 (m, 1H), 8.38 (s, 1H), 8.24–8.21 (m, 1H), 7.70–7.68 (m, 1H), 7.60–7.58 (m, 3H), 7.50–7.47 (m, 2H), 4.44 (q, J=7.3 Hz, 2H), 1.44 (t, J=6.9 Hz, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  163.4, 145.5, 137.9, 137.3, 134.8, 133.7, 130.6, 130.0, 129.8, 128.9, 128.7, 128.0, 127.2, 124.6, 111.2, 108.6, 60.8, 14.4. HRMS (ESI) calcd for C<sub>20</sub>H<sub>14</sub>BrClN<sub>2</sub>O<sub>2</sub>: 429.0005 (M+H<sup>+</sup>), found: 428.9992.

4.1.7. *Ethyl* 6-bromo-9-fluoro-5-phenylpyrazolo[5,1-a]isoquinoline-1-carboxylate (**3g**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.83–9.80 (m, 1H), 8.38 (s, 1H), 8.33–8.30 (m, 1H), 7.62–7.58 (m, 3H), 7.52–7.47 (m, 3H), 4.44 (q, J=7.3 Hz, 2H), 1.44 (t, J=7.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  163.5, 162.0 (d,  $J_{(C,F)}=247.9$  Hz), 145.4, 137.7, 137.1, 133.8, 130.0, 129.9, 129.8, 128.7, 126.3, 125.2 (d,  $J_{(C,F)}=11.4$  Hz), 118.9 (d,  $J_{(C,F)}=23.8$  Hz), 113.5 (d,  $J_{(C,F)}=26.7$  Hz), 111.3, 108.5, 60.8, 14.4. HRMS (ESI) calcd for  $C_{20}H_{14}BrFN_2O_2$ : 435.0120 (M+Na<sup>+</sup>), found: 435.0114.

4.1.8. Ethyl 6-bromo-8-fluoro-5-phenylpyrazolo[5,1-a]isoquinoline-1-carboxylate (**3h**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  10.08–10.05 (m, 1H), 8.37 (s, 1H), 7.99–7.96 (m, 1H), 7.60–7.48 (m, 6H), 4.42 (q, *J*=6.9 Hz, 2H), 1.43 (t, *J*=6.9 Hz, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  163.7, 163.2 (d, *J*<sub>(C,F)</sub>=248.9 Hz), 144.9, 138.9, 138.1, 132.4, 132.3, 130.9 (d, *J*<sub>(C,F)</sub>=9.5 Hz), 130.0, 129.9, 128.8, 119.9, 116.5 (d, *J*<sub>(C,F)</sub>=22.9 Hz), 112.3 (d, *J*<sub>(C,F)</sub>=25.7 Hz), 110.7, 107.4, 60.6, 14.4. HRMS (ESI) calcd for C<sub>20</sub>H<sub>14</sub>BrFN<sub>2</sub>O<sub>2</sub>: 435.0120 (M+Na<sup>+</sup>), found: 435.0103.

4.1.9. Ethyl 6-bromo-5-cyclopropyl-8-fluoropyrazolo[5,1-a]isoquino-line-1-carboxylate (**3i**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.97–9.94 (m, 1H), 8.46 (s, 1H), 7.93 (dd, *J*=7.8, 2.8 Hz, 1H), 7.39–7.34 (m, 1H), 4.41 (q, *J*=7.3 Hz, 2H), 2.38–2.33 (m, 1H), 1.45–1.35 (m, 3H), 1.26–1.24 (m, 4H). <sup>13</sup>C NMR (100 MHz)  $\delta$  163.8, 163.3 (d, *J*<sub>(C,F)</sub>=249.8 Hz), 145.0, 139.0, 138.2, 132.5, 131.1, 131.0, 119.9, 116.6 (d, *J*<sub>(C,F)</sub>=22.9 Hz), 112.4 (d, *J*<sub>(C,F)</sub>=25.8 Hz), 107.6, 60.6, 31.4, 30.2, 14.4, 10.4. HRMS (ESI) calcd for C<sub>17</sub>H<sub>14</sub>BrFN<sub>2</sub>O<sub>2</sub>: 399.0120 (M+Na<sup>+</sup>), found: 399.0111.

4.1.10. Ethyl 6-bromo-5-butyl-8-fluoropyrazolo[5,1-a]isoquinoline-1-carboxylate (**3***j*). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.96–9.93 (m, 1H), 8.45 (s, 1H), 7.86 (dd, *J*=8.2, 2.3 Hz, 1H), 7.36–7.33 (m, 1H), 4.42 (q *J*=7.3 Hz, 2H), 3.53 (t, *J*=7.8 Hz, 2H), 1.78–1.73 (m, 2H), 1.54 (q, *J*=7.4 Hz, 2H), 1.45 (t, *J*=7.4 Hz, 3H), 1.00 (t, *J*=7.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  163.8, 163.4 (d, *J*<sub>(C,F)</sub>=249.8 Hz), 145.3, 140.6, 137.9, 132.1, 131.2, 131.1, 119.9, 116.4 (d, *J*<sub>(C,F)</sub>=21.9 Hz), 112.3 (d, *J*<sub>(C,F)</sub>=24.5 Hz), 109.6, 107.8, 60.7, 32.1, 28.9, 14.5, 14.0. HRMS (ESI) calcd for C<sub>18</sub>H<sub>18</sub>BrN<sub>2</sub>O<sub>2</sub>: 393.0614 (M+H<sup>+</sup>), found: 393.0615.

# 4.2. General procedure for generation of 6-bromo-1,2,3,10*b*tetrahydropyrazolo[5,1-*a*]isoquinoline 4 via three-component reaction of *N*-(2-alkynylbenzylidene)hydrazide 1, $\alpha$ , $\beta$ unsaturated carbonyl compound 2, with bromine

A mixture of *N*'-(2-alkynylbenzylidene)hydrazide **1** (0.2 mmol) and bromine (0.24 mmol, 1.2 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) was stirred at room temperature under air atmosphere for 10 min. Then K<sub>3</sub>PO<sub>4</sub> (0.3 mmol, 1.5 equiv) and  $\alpha$ , $\beta$ -unsaturated carbonyl compound (0.2 mmol, 1.0 equiv) were added into the reaction mixture. The reaction mixture was stirred at 10 °C until completion of the reaction. The mixture was then quenched with saturated NH<sub>4</sub>Cl (aq), extracted with ethyl acetate (10 mL×3). The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to provide the desired product **4**.

4.2.1. Ethyl 6-bromo-5-phenyl-3-tosyl-1,2,3,10b-tetrahydropyrazolo-[5,1-a]isoquinoline-1-carboxylate (**4a**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.49–7.47 (m, 1H), 7.44–7.43 (m, 1H), 7.39–7.37 (m, 2H), 7.36–7.30 (m, 2H), 7.28–7.20 (m, 2H), 7.16–7.13 (m, 3H), 6.95 (t, *J*=7.8 Hz, 1H), 6.40 (d, *J*=7.8 Hz, 1H), 5.14 (d, *J*=8.7 Hz, 1H), 4.17–4.10 (m, 1H), 3.73–3.63 (m, 3H), 3.59–3.53 (m, 1H), 2.44 (s, 3H), 0.78 (t, *J*=7.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  171.6, 145.3, 144.6, 136.3, 133.0, 129.6, 129.4, 129.3, 129.0, 128.7, 127.9, 127.8, 127.6, 127.2, 126.1, 101.3, 65.1, 61.4, 52.7, 47.1, 21.8, 13.6. HRMS (ESI) calcd for C<sub>27</sub>H<sub>25</sub>BrN<sub>2</sub>O<sub>4</sub>S: 575.0616 (M+Na<sup>+</sup>), found: 575.0596.

4.2.2. Methyl 6-bromo-5-phenyl-3-tosyl-1,2,3,10b-tetrahydropyrazolo[5,1-a]isoquinoline-1-carboxylate (**4b**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.51–7.49 (m, 1H), 7.43–7.37 (m, 2H), 7.35–7.29 (m, 3H), 7.29–7.21 (m, 2H), 7.14 (d, *J*=8.3 Hz, 3H), 6.96 (t, *J*=7.8 Hz, 1H), 6.40 (d, *J*=7.8 Hz, 1H), 5.17 (d, *J*=8.7 Hz, 1H), 4.20 (dd, *J*=9.2, 3.6 Hz, 1H), 3.72 (dd, *J*=7.3, 5.1 Hz, 1H), 3.64–3.60 (m, 1H), 3.23 (s, 3H), 2.47 (s, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  172.1, 145.1, 144.6, 136.3, 133.0, 130.8, 129.6, 129.4, 129.0, 128.7, 127.8, 127.7, 127.6, 126.1, 101.4, 65.1, 52.9, 52.1, 47.0, 21.8. HRMS (ESI) calcd for C<sub>26</sub>H<sub>23</sub>BrN<sub>2</sub>O<sub>4</sub>S: 561.0460 (M+Na<sup>+</sup>), found: 561.0422.

4.2.3. Butyl 6-bromo-5-phenyl-3-tosyl-1,2,3,10b-tetrahydropyrazolo-[5,1-a]isoquinoline-1-carboxylate (**4c**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.52–7.50 (m, 1H), 7.47–7.45 (m, 1H), 7.41–7.40 (m, 2H), 7.37–7.29 (m, 3H), 7.24–7.22 (m, 1H), 7.18–7.16 (m, 3H), 6.98 (t, *J*=7.3 Hz, 1H), 6.44 (d, *J*=7.4 Hz, 1H), 5.17 (d, *J*=8.2 Hz, 1H), 4.20 (dd, *J*=8.7, 3.7 Hz, 1H), 3.75–3.66 (m, 2H), 3.62–3.52 (m, 2H), 2.47 (s, 3H), 1.36–1.28 (m, 2H), 0.94–0.87 (m, 2H), 0.83–0.79 (m, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  171.8, 145.2, 144.5, 136.3, 133.0, 130.8, 129.6, 129.4, 129.3, 129.0, 128.7, 127.9, 127.8, 127.7, 127.6, 127.2, 126.1, 101.3, 65.3, 65.1, 52.8, 47.2, 30.1, 21.8, 19.0, 13.7 HRMS (ESI) calcd for C<sub>29</sub>H<sub>29</sub>BrN<sub>2</sub>O<sub>4</sub>S: 603.0929 (M+Na<sup>+</sup>), found: 603.0924.

4.2.4. Biphenyl-4-yl 6-bromo-5-phenyl-3-tosyl-1,2,3,10b-tetrahydropyrazolo[5,1-a]isoquinoline-1-carboxylate (**4d**). White solid, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.61–7.59 (m, 1H), 7.47–7.45 (m, 2H), 7.43–7.37 (m, 7H), 7.37–7.36 (m, 1H), 7.31–7.27 (m, 3H), 7.26–7.21 (m, 2H), 7.18–7.16 (m, 2H), 6.96 (dt, *J*=7.4, 0.9 Hz, 1H), 6.44 (m, 3H), 5.35 (d, *J*=9.2 Hz, 1H), 4.31 (dd, *J*=8.7, 3.7 Hz, 1H), 3.89–3.83 (m, 1H), 3.79–3.75 (m, 1H), 2.44 (s, 3H). <sup>13</sup>C NMR (100 MHz)  $\delta$  171.0, 149.6, 145.4, 144.8, 140.3, 139.2, 136.2, 133.0, 130.8, 129.7, 129.5, 129.4, 128.9, 128.6, 128.2, 127.9, 127.7, 127.6, 127.5, 127.3, 127.2, 126.4, 121.4, 101.3, 65.4, 52.8, 47.5, 21.8. HRMS (ESI) calcd for C<sub>37</sub>H<sub>29</sub>BrN<sub>2</sub>O<sub>4</sub>S: 699.0929 (M+Na<sup>+</sup>), found: 699.0923.

#### Acknowledgements

Financial support from National Natural Science Foundation of China (20972030) and the Science & Technology Commission of Shanghai Municipality (09JC1404902) is gratefully acknowledged.

#### Supplementary data

Experimental procedures, characterization data, <sup>1</sup>H, and <sup>13</sup>C NMR spectra of compounds **3** and **4**. Supplementary data associated with this article can be found in online version at doi:10.1016/ j.tet.2010.08.052.

#### **References and notes**

- (a) Walsh, D. P.; Chang, Y.-T. *Chem. Rev.* 2006, *106*, 2476; (b) Arya, P.; Chou, D. T. H.; Baek, M.-G. *Angew. Chem., Int. Ed.* 2001, *40*, 339; (c) Schreiber, S. L. *Science* 2000, 287, 1964.
- For selected examples, see: (a) Bentley, K. W. The Isoquinoline Alkaloids; Harwood Academic: Australia, 1998; Vol. 1; (b) Phillipson, J. D.; Roberts, M. F.; Zenk, M. H. The Chemistry and Biology of Isoquinoline Alkaloids; Springer: New York, NY, 1985; (c) Balasubramanian, M.; Keay, J. G. Isoquinoline Synthesis. In Comprehensive Heterocyclic Chemistry II; McKillop, A. E., Katrizky, A. R., Rees, C. W., Scrivem, E. F. V., Eds.; Elsevier: Oxford, 1996; Vol. 5, pp 245–300; (d) For a review on the synthesis of isoquinoline alkaloid, see: Chrzanowska, M.; Rozwadowska, M. D. Chem. Rev. 2004, 104, 3341.
- 3. For selected examples, see: (a) Trotter, B. W.; Nanda, K. K.; Kett, N. R.; Regan, C. P.; Lynch, J. J.; Stump, G. L.; Kiss, L.; Wang, J.; Spencer, R. H.; Kane, S. A.; White, R. B.; Zhang, R.; Anderson, K. D.; Liverton, N. J.; McIntyre, C. J.; Beshore, D. C.; Hartman, G. D.; Dinsmore, C. J. J. Med. Chem. 2006, 49, 6954; (b) Ramesh, P.; Reddy, N. S.; Venkateswarlu, Y. J. Nat. Prod. 1999, 62, 780; (c) Kaneda, T.; Takeuchi, Y.; Matsui, H.; Shimizu, K.; Urakawa, N.; Nakajyo, S. J. Pharmacol. Sci. 2005, 98, 275; (d) Mikami, Y.; Yokoyama, K.; Tabeta, H.; Nakagaki, K.; Arai, T. J. Pharm. Dyn. 1981, 4, 282; (e) Marchand, C.; Antony, S.; Kohn, K. W.; Cushman, M.; Ioanoviciu, A.; Staker, B. L.; Burgin, A. B.; Stewart, L.; Pommier, Y. Mol. Cancer Ther. 2006, 5, 287; (f) Pettit, G. R.; Gaddamidi, V.; Herald, D. L.; Singh, S. B.; Cragg, G. M.; Schmidt, J. M.; Boettner, F. E.; Williams, M.; Sagawa, Y. J. Nat. Prod. 1986, 49, 995.

- (a) Bailly, C. Curr. Med. Chem. AntiCancer Agents 2004, 4, 363; (b) Marco, E.; Laine, W.; Tardy, C.; Lansiaux, A.; Iwao, M.; Ishibashi, F.; Bailly, C.; Gago, F. J. Med. Chem. 2005, 48, 3796.
- (a) Reddy, M. V. R.; Rao, M. R.; Rhodes, D.; Hansen, M. S. T.; Rubins, K.; Bushman, F. D.; Venkateswarlu, Y.; Faulkner, D. J. *J. Med. Chem.* **1999**, *42*, 1901; (b) Aubry, A.; Pan, X.-S.; Fisher, L. M.; Jarlier, V.; Cambau, E. Antimicro. Agents Chemother. **2004**, *48*, 1281.
- For reviews, see: (a) Montgomery, J. Angew. Chem., Int. Ed. 2004, 43, 3890; (b) Negishi, E.; Coperet, C.; Ma, S.; Liou, S. Y.; Liu, F. Chem. Rev. 1996, 96, 365; (c) Tietze, L. F. Chem. Rev. 1996, 96, 115; (d) Grigg, R.; Sridharan, V. J. Organomet. Chem. 1999, 576, 65; (e) Miura, T.; Murakami, M. Chem. Commun. 2007, 217; (f) Malacria, M. Chem. Rev. 1996, 96, 289; (g) Nicolaou, K. C.; Montagnon, T.; Snyder, S. A. Chem. Commun. 2003, 551; (h) Nicolaou, K. C.; Montagnon, T.; Bulger, P. G. Angew. Chem., Int. Ed. 2006, 45, 7134; (i) Enders, D.; Grondal, C.; Hüttl, M. R. M. Angew. Chem., Int. Ed. 2007, 46, 1570; (j) Tietze, L. F.; Brasche, G.; Gericke, K. Domino Reactions in Organic Synthesis; Wiley-VCH: Weinheim, Germany, 2006.
   (a) Yu, X.; Wu, J. J. Comb. Chem. 2010, 12, 238; (b) Chen, Z.; Yu, X.; Su, M.; Yang,
- 7. (a) Yu, X.; Wu, J. J. Comb. Chem. 2010, 12, 238; (b) Chen, Z.; Yu, X.; Su, M.; Yang, X.; Wu, J. Adv. Synth. Catal. 2009, 351, 2702; (c) Ding, Q.; Wang, Z.; Wu, J. J. Org. Chem. 2009, 74, 921; (d) Yu, X.; Wu, J. J. Comb. Chem. 2009, 11, 895; (e) Chen, Z.; Ding, Q.; Yu, X.; Wu, J. Adv. Synth. Catal. 2009, 351, 1692; (f) Yu, X.; Yang, X.; Wu,

J. Org. Biomol. Chem. **2009**, 7, 4526; (g) Yu, X.; Ding, Q.; Chen, Z.; Wu, J. Tetrahedron Lett. **2009**, 50, 4279; (h) Ding, Q.; Wu, J. Adv. Synth. Catal. **2008**, 350, 1850; (i) Ding, Q.; Wu, J. Org. Lett. **2007**, 9, 4959; (j) Gao, K.; Wu, J. J. Org. Chem. **2007**, 72, 8611; (k) Sun, W.; Ding, Q.; Sun, X.; Fan, R.; Wu, J. J. Comb. Chem. **2007**, 9, 690.

- S. For selected examples, see: (a) Yu, X.; Chen, Z.; Yang, X.; Wu, J. J. Comb. Chem.
  2010, 12, 374; (b) Chen, Z.; Yang, X.; Wu, J. Chem. Commun. 2009, 3469; (c) Chen,
  Z.; Su, M.; Yu, X.; Wu, J. Org. Biomol. Chem. 2009, 7, 4641; (d) Ye, S.; Yang, X.;
  Wu, J. Chem. Commun. 2010, 5238.
- For selected examples of multi-component reactions, see: (a) Zhu, J.; Bienayme, H. Multicomponent Reactions; Wiley-VCH: Weinheim, Germany, 2005; (b) Ramon, D. J.; Yus, M. Angew. Chem., Int. Ed. 2005, 44, 1602; (c) Nair, V.; Rajesh, C.; Vinod, A. U.; Bindu, S.; Sreekenth, A. R.; Balagopal, L. Acc. Chem. Res. 2003, 899; (d) Orru, R. V. A.; de Greef, M. Synthesis 2003, 1471; (e) Balme, G.; Bossharth, E.; Monteiro, N. Eur. J. Org. Chem. 2003, 4101; (f) Dömling, A.; Ugi, I. Angew. Chem., Int. Ed. 2000, 6, 3321; (h) Weber, L.; Illgen, K.; Almstetter, M. Synlett 1999, 366; (i) Ugi, I.; Domling, A.; Werner, B. J. Heterocycl. Chem. 2000, 37, 647; (j) Zhu, J. Eur. J. Org. Chem. 2003, 1133; (k) Hulme, C.; Gore, V. Curr. Med. Chem. 2003, 10, 51; (l) Weber, L. Curr. Med. Chem. 2002, 9, 1241.
- 10. Ding, Q.; Chen, Z.; Yu, X.; Peng, Y.; Wu, J. Tetrahedron Lett. 2009, 50, 340.